|
June 30, 2008
Shareholder Update:
The following is a recap of events, agreements and
other developments that have had or will have an impact on your
investment in MDEChem, Inc.
At last year’s shareholder meeting the company in
order to raise capital offered attractive promissory notes. We
raised needed capital in increments of $5000 per note. Each note is
backed by 100 Units of EnviroFuels, a 12% interest rate and an
option to purchase 10,000 shares of MaxHeal stock @ $.50 a share
until 12/31/2008.
We were also fortunate to have raised capital by
selling stock at market prices to investors in order to raise money
to keep us in the black in 2005, 2006 and 2007. This stock was sold
to investors with an option to buy a specific amount stock at an
established favorable rate as an incentive.
All of these incentive options have either run out
or will on 12/31/2008. The Directors know that without these
investors the company would not have survived. When we established
these options we miscalculated our development time lines. In return
for these investors confidence in us, all options have been extended
to 12/31/2009.
Investors will receive revised promissory notes or
revised option letters for their files.
Since last June---
- In August 2007 the MaxHealus.com web site was established with
Stores On Line to sell product. This web site can take
orders from individual customers and provides MaxHeal with a
product advertising and product information platform.
Sellion, a brand
development company, with a focus on medical products that provide
solutions for today’s most common ailments was engaged by MDEChem
on May 1, 2008 to aid MaxHeal in the marketing, logistics, product
development and the sales/ distribution of our products starting
with MaxHeal™ Skin Restoration Gel.
Sellion has provided research and analysis of our
product and has developed a MaxHeal™ Business Plan for marketing,
public relations, advertising, packaging and point of sale
presentations.
In the future commercialization of MaxHeal as a
brand they will be our marketing and sales management. Their client
portfolio includes Sierra Life Sciences, Visible Youth "The science
of skin care", Healthpoint Technologies, Kingbio, imVia, aeura,
Light for Health, Sankom of Switzerland and –Heel.
- Planck Consulting LLC, was engaged by MDEChem via an
"Agreement" signed May 1st. 2008. Planck will provide
business consulting services and assist MDEChem’s business
development efforts such as: licensing agreements, identifying new
products, developing and documenting new "USE" patents, creating
new product pamphlets, new product documentation and to assist in
the development of new business contacts.
- A License Agreement was signed on June 1, 2008 between
MDEChem, Inc. and Falcion, LLC. This license grants the
exclusive agricultural/horticultural application and treatment
rights to Falcion, LLC. This license provides exclusive and
worldwide development and marketing rights of products,
applications and treatments based upon MDEChem’s patented
technology.
In July 2007 the first domestically produced MaxHeal product
was packaged at FNC Medical in Ventura, CA. This production
consisted of 27,000 1.75oz tubes of MaxHeal Skin Restoration
Gel.
- In August 2007 MDEChem/MaxHeal leased a 1600 S.F. building in
Floresville, TX for office, lab work and warehousing.
- In January 2008 MDEChem obtained at no cost the trademark for
"Phosfamid" from EnviroFuels, LLC and has registered it for our
use in the future.
- A 504 offering that was intended to raise $1,000,000 through
the sale of MaxHeal, Inc shares was finalized in early 2008. The
marketing of this Offering failed and the company has since
withdrawn this Offering until we can find a qualified group to
handle the marketing.
In March 2008 to
raise capital to continue operations the company
sold a small percentage of EnviroFuels, LLC
Units in order to go forward with our market and product
development programs.
- The sales at EnviroFuels in 2007 fell far short of original
management projections and adjustments have been made to their
management.
We are working to introduce to the
market a few new products. One of those products will be a .75-oz
version of our current 1.75-oz Skin Restoration Gel.
- Other products include a Liquid MaxHeal, a MaxHeal Joint
Cream, a MaxHeal Gel with increased percentages of aloe and buffer
and various carriers. Our focus is continuing to be on topical
applications of our buffer and substituting Ibuprofen or
Acetaminophen for Salicylic Acid in certain products.
The Board plans to have a shareholder meeting in
the near future when we can set up an agreeable date and
location.
September
2007
MDEChem announces the
production by MaxHeal, Inc. of MaxHeal Skin Restoration Gel.
This Gel is a topical pain relieving analgesic developed from
MDEChem's patented technology. See the MaxHeal Gel page
for further information.
May 18, 2007
At the annual Shareholders Meeting in Houston
on May 18th Fred Fischer, Shannon McCoy and Paul W. Sack were
re-elected for another year to MDEChem's Board of Directors.
The current Board of Directors consists
of:
Fred
Fischer, Waukesha, WI
Shannon
McCoy, Atlanta, GA
Paul W. Sack, Floresville,
TX
April 14, 2004
Paul W. Sack named President and CEO
MDECHEM, INC. Board of Directors announces the
appointment of Mr. Paul W. Sack to the position of President and CEO
of the corporation.
Mr. Sack replaces Mr. Frank Defalco, who had
previously announced his retirement.
| 
